Wilson offers these three AIM names worth watching just now:
1) Amryt (a pharma firm)
2) MPAC (packaging)
3) Renalytix AI (artificial intelligence for kidney disease)
Lee Wild, head of equity strategy at interactive investor says investors have liked promising small-cap miners, oil exploration companies and tech firms exploiting a lucrative niche, or stocks that just happen to be in the right place at the right time.
“Many of the biggest risers during the pandemic recovery phase have had a new story to fuel buying. Most notable have been the Covid-19 testing stocks like Novacyt, Genedrive and a dozen others whose shares have soared as much as 8,000% in quick time,” he adds.
“Picking these stocks requires research, courage and a lot of luck, but the promise of returns you’d struggle to find anywhere else is a constant lure for investors.”
Fed chair Jerome Powell has pumped in billions to help the US economy
AFP/Getty Images
So one side effect of the pandemic has been to remind investors that smaller companies and the markets they trade on, like AIM, have far greater growth potential than larger companies operating in more mature markets.
This route isn’t for the faint of heart. There’s greater risk involved for sure.
And many smaller companies will require new money to fund investment and growth. At the moment, that’s not a problem, but a deterioration in the lending environment could put less stable businesses at risk.
But if you feel confident about your strategy, you could do well from the smaller stocks. As Jim Slater once said: “Elephants don’t gallop.”